CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
Ganaxolone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03460756
NCT03460756Phase 2Completed
CompareCT.gov

A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression

Marinus Pharmaceuticals·interventional·Posted Mar 9, 2018·Updated Aug 18, 2023

In Brief

A Phase 2 clinical trial evaluating Ganaxolone and Placebo for Depressive Disorder and 9 related conditions. Completed, enrolled 84 participants across 33 sites.

Detailed Summary

A clinical study to evaluate safety, tolerability and efficacy of oral administration of ganaxolone in women with postpartum depression

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartDec 28, 2017
Primary CompletionJul 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.3 years ago

Interventions

Ganaxolonedrug

Oral

Placebodrug

Oral